AVANOS MEDICAL Files 8-K on Operations & Financial Condition
Ticker: AVNS · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1606498
| Field | Detail |
|---|---|
| Company | Avanos Medical, INC. (AVNS) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-filing
TL;DR
**AVNS just dropped an 8-K on its financials, time to check the numbers!**
AI Summary
AVANOS MEDICAL, INC. filed an 8-K on January 4, 2024, to report on its Results of Operations and Financial Condition, along with Financial Statements and Exhibits. This filing, under SEC File Number 001-36440, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a current snapshot of the company's health and operational efficiency, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with the latest financial and operational data for AVANOS MEDICAL, INC., crucial for assessing the company's current performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate new risks or significant events.
Analyst Insight
A smart investor would review the detailed financial statements and results of operations once they become available to understand the company's performance trends and financial health.
Key Players & Entities
- AVANOS MEDICAL, INC. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — date of the earliest event reported and filing date
- 001-36440 (string) — SEC file number for AVANOS MEDICAL, INC.
- Delaware (string) — state of incorporation for AVANOS MEDICAL, INC.
- 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (string) — address of principal executive offices for AVANOS MEDICAL, INC.
- 844-428-2667 (string) — registrant's telephone number
- AVNS (string) — trading symbol for Common Stock of AVANOS MEDICAL, INC.
- New York Stock Exchange (string) — exchange where AVNS Common Stock is registered
FAQ
What is the purpose of this 8-K filing by AVANOS MEDICAL, INC.?
The purpose of this 8-K filing, dated January 4, 2024, is to report on the company's Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' sections.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, which is also the date of the report.
What is the trading symbol and exchange for AVANOS MEDICAL, INC.'s Common Stock?
The trading symbol for AVANOS MEDICAL, INC.'s Common Stock is AVNS, and it is registered on the New York Stock Exchange.
Where are the principal executive offices of AVANOS MEDICAL, INC. located?
The principal executive offices of AVANOS MEDICAL, INC. are located at 5405 Windward Parkway, Suite 100 South, Alpharetta, Georgia 30004.
Is AVANOS MEDICAL, INC. considered an emerging growth company according to this filing?
No, AVANOS MEDICAL, INC. is not indicated as an emerging growth company, as the box for 'Emerging growth company' is unchecked in the filing.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-04 08:02:34
Key Financial Figures
- $0.01 — nge on which registered Common Stock - $0.01 Par Value AVNS New York Stock Exchange
Filing Documents
- avns-20240104.htm (8-K) — 27KB
- avns_01042024xex991.htm (EX-99.1) — 18KB
- avanoslogoa08a.jpg (GRAPHIC) — 15KB
- avns-20240104_g1.jpg (GRAPHIC) — 15KB
- 0001606498-24-000002.txt ( ) — 238KB
- avns-20240104.xsd (EX-101.SCH) — 2KB
- avns-20240104_lab.xml (EX-101.LAB) — 24KB
- avns-20240104_pre.xml (EX-101.PRE) — 13KB
- avns-20240104_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On January 4, 2024, Avanos Medical, Inc. (the "Company") issued a press release that announced selected, unaudited preliminary financial results for the quarter and full-year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Avanos Medical, Inc. on January 4, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVANOS MEDICAL, INC. Date: January 4, 2024 By: /s/ Mojirade James Mojirade James Senior Vice President and General Counsel